ClinicalTrials.gg
CompletedNCT05024032SURMOUNT-CNUpdated Jan 19, 2024Results posted

A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)

A Phase 3 interventional study of Tirzepatide and Placebo in Obesity, Overweight and Metabolism and Nutrition Disorder, sponsored by Eli Lilly and Company. Completed at 29 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-19.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 104 studies testing tirzepatide in Obesity — 60 open to participants now, 79 under way, 14 of them phase 3. Tirzepatide · Obesity.

Enrollment
29th of 104
210 · median 69
Started
2021
with 5 others
Phase 3
26 of 104
7 open now
Registered
10th of 104
by date
Lead sponsor
34 of 104
Eli Lilly and Company

Among the 104 studies testing tirzepatide in Obesity, this one is the 29th largest by enrollment, is one of 6 that started in 2021, is one of 26 in phase 3, and was the 10th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

60 of the 104 studies testing tirzepatide in Obesity are open now, in 12 countries. Recruiting first, the newest first:

55 more — sign in →

By country, each count listing its studies:

All 60 open studies →

About tirzepatide

Tirzepatide: first FDA approval 2022 (MOUNJARO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing tirzepatide in Obesity, or all of them as a file.
02

Study summary

This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight.

The main purpose is to learn more about how tirzepatide affects body weight.

03

Conditions studied

  • Obesity
  • Overweight
  • Metabolism and Nutrition Disorder
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease
  • Have a history of at least one self-reported unsuccessful dietary effort to lose body weight

Exclusion criteria

Exclusion Criteria:

  • Have Diabetes Mellitus
  • Have a self-reported change in body weight >5 kg within 3 months prior to screening
  • Have obesity induced by other endocrinological disorders
  • Have had a history of chronic or acute pancreatitis
  • Have a history of significant active or unstable Major Depressive Disorder (MDD) or other severe psychiatric disorder within the last 2 years
  • Have any lifetime history of a suicide attempt
  • Have a family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    10 Milligrams (mg) Tirzepatide

    Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).

    Drug: Tirzepatide

  • Experimental
    15 mg Tirzepatide

    Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.

    Drug: Tirzepatide

  • Placebo comparator
    Placebo

    Participants received matching placebo SC QW.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY3298176

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Mean Percent Change From Baseline in Body Weight

    Mean Percent Change from Baseline in Body Weight. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + Sex + Presence of Comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  2. Percentage of Participants Who Achieve ≥5% Body Weight Reduction

    Percentage of Participants who Achieve ≥5% Body Weight Reduction. A logistic regression model was used for this analysis.

    Time frame: Week 52

Secondary outcomes

  1. Mean Change From Baseline in Body Weight

    Mean Change from Baseline in Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 20

  2. Percentage of Participants Who Achieve ≥10% Body Weight Reduction

    Percentage of Participants who Achieve ≥10% Body Weight Reduction. A logistic regression model was used for this analysis.

    Time frame: Week 52

  3. Percentage of Participants Who Achieve ≥15% Body Weight Reduction

    Percentage of Participants who Achieve ≥15% Body Weight Reduction. A logistic regression model was used for this analysis.

    Time frame: Week 52

  4. Mean Change From Baseline in Waist Circumference

    Mean Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  5. Mean Change From Baseline in Absolute Body Weight

    Mean Change from Baseline in Absolute Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  6. Mean Change From Baseline in Body Mass Index (BMI)

    Mean Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  7. Mean Change From Baseline in Hemoglobin A1c (HbA1c)

    Mean Change from Baseline in HbA1c. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  8. Mean Change From Baseline in Fasting Glucose (FSG)

    Mean Change from Baseline in FSG. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  9. Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

    The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  10. Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

    The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  11. Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model with Variable = Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  12. Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  13. Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model using log (Actual measurement/Baseline) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  14. Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  15. Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  16. Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  17. Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  18. Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

  19. Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)

    LS mean was determined using MMRM model with log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

    Time frame: Baseline, Week 52

07

Results

Posted Jan 19, 2024

Participant flow

Participant flow — Overall Study
Milestone10 Milligrams (mg) Tirzepatide15 mg TirzepatidePlacebo
Started707169
Received at least one dose707169
Completed696765
Not completed144
Withdrew: Withdrawal by subject034
Withdrew: Adverse event010
Withdrew: Protocol deviation100

Outcome measures

PrimaryMean Percent Change From Baseline in Body Weight

Mean Percent Change from Baseline in Body Weight. Least squares (LS) mean was determined using mixed model repeated measures (MMRM) model with Baseline + Sex + Presence of Comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Mean Percent Change From Baseline in Body Weight
Percent change10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Percent Change From Baseline in Body Weight-14.4 ± 0.98-19.9 ± 1.01-2.4 ± 1.00
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -12.0 · 95% CI -14.8 to -9.3
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -17.5 · 95% CI -20.3 to -14.8
PrimaryPercentage of Participants Who Achieve ≥5% Body Weight Reduction

Percentage of Participants who Achieve ≥5% Body Weight Reduction. A logistic regression model was used for this analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥5% Body Weight Reduction
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieve ≥5% Body Weight Reduction91.4392.6529.41
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 23.11 · 95% CI 8.80 to 60.69
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 26.53 · 95% CI 9.61 to 73.24
SecondaryMean Change From Baseline in Body Weight

Mean Change from Baseline in Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 20
Reported as:
Least squares mean · kilograms (kg)
Mean Change From Baseline in Body Weight
kilograms (kg)10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Body Weight-9.0 ± 0.59-11.1 ± 0.61-1.8 ± 0.60
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -7.2 · 95% CI -8.8 to -5.5
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -9.2 · 95% CI -10.9 to -7.5
SecondaryPercentage of Participants Who Achieve ≥10% Body Weight Reduction

Percentage of Participants who Achieve ≥10% Body Weight Reduction. A logistic regression model was used for this analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥10% Body Weight Reduction
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieve ≥10% Body Weight Reduction70.083.8214.71
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 13.19 · 95% CI 5.63 to 30.89
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 28.58 · 95% CI 11.23 to 72.71
SecondaryPercentage of Participants Who Achieve ≥15% Body Weight Reduction

Percentage of Participants who Achieve ≥15% Body Weight Reduction. A logistic regression model was used for this analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieve ≥15% Body Weight Reduction
Percentage of participants10 mg Tirzepatide15 mg TirzepatidePlacebo
Percentage of Participants Who Achieve ≥15% Body Weight Reduction48.5772.062.94
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 25.64 · 95% CI 6.68 to 98.49
  • 15 mg Tirzepatide vs Placebo · Regression, Logistic · p = <0.001 · Odds ratio (or): 69.79 · 95% CI 17.69 to 275.37
SecondaryMean Change From Baseline in Waist Circumference

Mean Change from Baseline in Waist Circumference. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · centimeters (cm)
Mean Change From Baseline in Waist Circumference
centimeters (cm)10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Waist Circumference-11.9 ± 0.83-16.4 ± 0.85-2.7 ± 0.84
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -9.2 · 95% CI -11.5 to -6.9
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -13.7 · 95% CI -16.0 to -11.3
SecondaryMean Change From Baseline in Absolute Body Weight

Mean Change from Baseline in Absolute Body Weight. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · kilograms (kg)
Mean Change From Baseline in Absolute Body Weight
kilograms (kg)10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Absolute Body Weight-13.1 ± 0.93-18.1 ± 0.95-2.1 ± 0.94
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -10.9 · 95% CI -13.5 to -8.3
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -16.0 · 95% CI -18.6 to -13.4
SecondaryMean Change From Baseline in Body Mass Index (BMI)

Mean Change from Baseline in BMI. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · kilograms per metres squared (kg/m^2)
Mean Change From Baseline in Body Mass Index (BMI)
kilograms per metres squared (kg/m^2)10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Body Mass Index (BMI)-4.7 ± 0.29-6.4 ± 0.30-0.8 ± 0.30
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -3.9 · 95% CI -4.8 to -3.1
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -5.6 · 95% CI -6.4 to -4.8
SecondaryMean Change From Baseline in Hemoglobin A1c (HbA1c)

Mean Change from Baseline in HbA1c. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percentage of HbA1c
Mean Change From Baseline in Hemoglobin A1c (HbA1c)
Percentage of HbA1c10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Hemoglobin A1c (HbA1c)-0.34 ± 0.032-0.35 ± 0.0330.03 ± 0.033
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.37 · 95% CI -0.46 to -0.28
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.39 · 95% CI -0.48 to -0.29
SecondaryMean Change From Baseline in Fasting Glucose (FSG)

Mean Change from Baseline in FSG. LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Fasting Glucose (FSG)
millimoles per liter (mmol/L)10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Fasting Glucose (FSG)-0.25 ± 0.050-0.33 ± 0.0520.22 ± 0.051
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.46 · 95% CI -0.61 to -0.32
  • 15 mg Tirzepatide vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -0.54 · 95% CI -0.69 to -0.40
SecondaryMean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score

The SF-36v2 acute form, 1-week recall assesses participants' health-related quality of life (HRQoL) on 8 domains: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional, and Mental Health. Information from these 8 domains is further aggregated into 2 health component summary scores: Physical Component Summary and Mental Component Summary. Items are answered on Likert scales of varying lengths. Scoring of each domain and both summary scores are norm based and presented in the form of T scores, with a mean of 50 and standard deviation of 10; higher scores indicate better levels of function and/or better health. Range cannot be specified in norm-based scores. LS mean was determined using analysis of covariance (ANCOVA) model using Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score
Score on a scale10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Short-Form-36 Health Survey Version 2 (SF-36v2) Acute Form Physical Functioning Domain Score2.0 ± 0.401.9 ± 0.420.8 ± 0.41
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = 0.044 · Ls mean difference: 1.2 · 95% CI 0.0 to 2.3
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = 0.050 · Ls mean difference: 1.2 · 95% CI 0.0 to 2.3
SecondaryMean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score

The IWQOL Lite-CT consists of 20 items, assessing 2 primary domains of obesity related HRQoL: Physical (7 items) and Psychosocial (13 items). A 5-item subset of the Physical domain - the Physical Function composite - is also supported. Items in the Physical Function composite describe physical impacts related to general and specific physical activities. Total score of IWQOL-Lite-CT composite ranges from 0 to 100, with higher scores reflecting better quality of life. LS mean was determined using ANCOVA model with Baseline + Sex + Presence of comorbidities + Treatment (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Score on a scale
Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score
Score on a scale10 mg Tirzepatide15 mg TirzepatidePlacebo
Mean Change From Baseline in Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT) Physical Function Composite Score11.2 ± 1.4412.0 ± 1.483.5 ± 1.48
Statistical analysis
  • 10 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 7.8 · 95% CI 3.7 to 11.8
  • 15 mg Tirzepatide vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 8.5 · 95% CI 4.4 to 12.7
SecondaryMean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model with Variable = Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimeters of Mercury (mmHg)
Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimeters of Mercury (mmHg)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Diastolic Blood Pressure (DBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)-6.1 ± 0.62-1.3 ± 0.88
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -4.8 · 95% CI -6.9 to -2.7
SecondaryMean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimeters of Mercury (mmHg)
Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimeters of Mercury (mmHg)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Systolic Blood Pressure (SBP) (Pooled Doses of Tirzepatide 10 mg and 15 mg)-9.6 ± 0.87-3.5 ± 1.24
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Mixed Models Analysis · p = <0.001 · Ls mean difference: -6.1 · 95% CI -9.1 to -3.1
SecondaryMean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model using log (Actual measurement/Baseline) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimoles per liter (mmol/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Total Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)-0.37 ± 0.055-0.06 ± 0.085
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: -0.31 · 95% CI -0.51 to -0.11
SecondaryMean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimoles per liter (mmol/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in High Density Lipoprotein (HDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)0.12 ± 0.0170.03 ± 0.023
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: 0.09 · 95% CI 0.03 to 0.14
SecondaryMean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model with Baseline + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimoles per liter (mmol/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Low Density Lipoprotein (LDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)-0.17 ± 0.056-0.11 ± 0.081
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: -0.06 · 95% CI -0.25 to 0.13
SecondaryMean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimoles per liter (mmol/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol (Pooled Doses of Tirzepatide 10 mg and 15 mg)-0.28 ± 0.019-0.03 ± 0.042
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: -0.25 · 95% CI -0.34 to -0.16
SecondaryMean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimoles per liter (mmol/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Triglycerides (Pooled Doses of Tirzepatide 10 mg and 15 mg)-0.63 ± 0.045-0.05 ± 0.099
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: -0.58 · 95% CI -0.79 to -0.37
SecondaryMean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model using log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimoles per liter (mmol/L)
Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)
millimoles per liter (mmol/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Free Fatty Acids (Pooled Doses of Tirzepatide 10 mg and 15 mg)-0.16 ± 0.013-0.10 ± 0.023
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: -0.07 · 95% CI -0.12 to -0.01
SecondaryMean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)

LS mean was determined using MMRM model with log (Actual Measurement) = log (Baseline) + Sex + Presence of comorbidities + Treatment + Time + Treatment\*Time (Type III sum of squares) as variables.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · milliunits per liter (mU/L)
Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)
milliunits per liter (mU/L)Tirzepatide Pooled AnalysisPlacebo
Mean Change From Baseline in Fasting Insulin (Pooled Doses of Tirzepatide 10 mg and 15 mg)-6.5 ± 0.42-0.2 ± 1.09
Statistical analysis
  • Tirzepatide Pooled Analysis vs Placebo · Ls mean difference: -6.3 · 95% CI -8.6 to -4.0

Adverse events

Collected over Baseline Through Safety Follow-Up (Up To Week 56). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
10 mg Tirzepatide0/70 (0%)3/70 (4.3%)61/70 (87.1%)
15 mg Tirzepatide0/71 (0%)8/71 (11.3%)56/71 (78.9%)
Placebo0/69 (0%)6/69 (8.7%)39/69 (56.5%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
Event10 mg Tirzepatide15 mg TirzepatidePlacebo
Abortion inducedSurgical and medical procedures0/350/351/33
Uterine polypReproductive system and breast disorders1/350/350/33
EpididymitisInfections and infestations0/350/361/36
Large intestine polypGastrointestinal disorders0/700/711/69
Covid-19Infections and infestations0/700/711/69
Urinary tract infectionInfections and infestations0/700/711/69
Rotator cuff syndromeMusculoskeletal and connective tissue disorders0/700/711/69
Cervical radiculopathyNervous system disorders0/700/711/69
Medical device removalSurgical and medical procedures0/700/711/69
Supraventricular tachycardiaCardiac disorders1/700/710/69
Most frequent other events
Showing 10 of 21
Most frequent other events
Event10 mg Tirzepatide15 mg TirzepatidePlacebo
DiarrhoeaGastrointestinal disorders28/7029/716/69
NauseaGastrointestinal disorders21/7023/714/69
Decreased appetiteMetabolism and nutrition disorders19/7020/718/69
Upper respiratory tract infectionInfections and infestations16/7017/7112/69
VomitingGastrointestinal disorders8/7014/713/69
Abdominal distensionGastrointestinal disorders13/709/711/69
HyperuricaemiaMetabolism and nutrition disorders3/705/718/69
GastroenteritisInfections and infestations8/702/710/69
Vaginal infectionInfections and infestations1/352/353/33
Hepatic function abnormalHepatobiliary disorders3/701/716/69

Baseline characteristics

All participants who received at least one dose of study drug.

Age, Continuous
Age, Continuous(years)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean34.70 ± 7.2435.80 ± 9.3337.80 ± 10.2436.10 ± 9.07
Sex: Female, Male
Sex: Female, Male(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Female353533103
Male353636107
Race (NIH/OMB)
Race (NIH/OMB)(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
American Indian or Alaska Native0000
Asian707169210
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
China707169210
Body Weight
Body Weight(kilograms (kg))10 mg Tirzepatide15 mg TirzepatidePlaceboTotal
Mean92.2 ± 16.291.3 ± 16.292.0 ± 15.891.8 ± 16.0
08

Study locations

29 sites
  • Beijing Tsinghua Changgung Hospital
    Beijing, Beijing 102202, China
  • The First Affiliated Hospital Chongqing Medical University
    Chongqing, Chongqing 400016, China
  • Zhujiang Hospital
    Guangzhou, Guangdong 510280, China
  • Shenzhen Second People's Hospital
    Shenzhen, Guangdong 518039, China
  • The First Hospital of Qinhuangdao
    Qinhuangdao, Hebei 066000, China
  • The Fourth Affiliated Hospital of Harbin Medical University
    Harbin, Heilongjiang 150001, China
  • The First Affiliated Hospital of Henan University of Science &Technology
    Luoyang, Henan 471003, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, Henan 450014, China
  • The First Affiliated Hospital of Nanhua University
    Hengyang, Hunan 421001, China
  • Changzhou No.2 People's Hospital
    Changzhou, Jiangsu 213000, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210011, China
  • Nanjing Medical University - Nanjing Jiangning Hospital
    Nanjing, Jiangsu 211100, China
  • Affiliated Hospital of Nantong University
    Nantong, Jiangsu 226001, China
  • Wuxi People's Hospital
    Wuxi, Jiangsu 214023, China
  • The Second Hospital of Jilin University
    Changchun, Jilin, China
  • Siping Central People's Hospital
    Siping, Jilin 136000, China
  • Jinan Central Hospital
    Jinan, Shandong 250013, China
  • Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 200032, China
  • Huadong Hospital Affiliated to Fudan University
    Shanghai, Shanghai 200040, China
  • Shanghai Hospital of Traditional Chinese Medicine
    Shanghai, Shanghai 200071, China
  • Qingpu Branch of Zhongshan Hospital, Fudan University
    Shanghai, Shanghai 201700, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, Shanxi 710077, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Tianjin Medical University General Hospital
    Tianjin, Tianjin 300052, China
  • The First People's Hospital of Hangzhou
    Hangzhou, Zhejiang 310006, China
  • Huzhou Central Hospital
    Huzhou, Zhejiang 313000, China
  • Ningbo First Hospital
    Ningbo, Zhejiang 315010, China
  • The Fifth People's Hospital of Shanghai
    Shanghai, 200240, China
  • Shanghai Minhang District Central Hospital
    Shanghai, 201199, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Dec 2022, 15 months.

Results were first posted in Jan 2024, 1 year after primary completion.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 15 months is below that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2021
First posted
Aug 27, 2021
StartActual
Sep 1, 2021
Primary completionActual
Dec 27, 2022
CompletionActual
Dec 27, 2022
Results first posted
Jan 19, 2024
Last update
Jan 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05024032
Responsible party
Sponsor
First posted
Aug 27, 2021
Start date
Sep 1, 2021
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022
Results posted
Jan 19, 2024
Last update
Jan 19, 2024

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tirzepatide

Start the discussion